Eligible studies were randomized controlled trials, prospective cohort studies, and clinical trials that met the following conditions: enrolled participants diagnosed with SLE based on recognized diagnostic criteria; investigated the use of Ld-IL-2 as a therapeutic intervention; compared IL-2 treatment to placebo, standard care, or no intervention; and reported relevant clinical or immunological outcomes, such as SLEDAI, BILAG, or SRI-4 response. The gene discussed is IL2; the disease is systemic lupus erythematosus.